Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Pegs Combined Market For Tasigna And Gleevec At $3.5 Billion

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm says market for chronic myeloid leukemia therapies will be further differentiated pending additional studies of Tasigna.

You may also be interested in...



Novartis Predicts $4 Billion Peak Sales For Gleevec/Tasigna Franchise

Only weeks into Tasigna's launch, Novartis is optimistic doctors will opt for nilotinib’s side-effect profile over Bristol’s Sprycel for Gleevec-resistant CML, Oncology CEO Epstein says.

Novartis Predicts $4 Billion Peak Sales For Gleevec/Tasigna Franchise

Only weeks into Tasigna's launch, Novartis is optimistic doctors will opt for nilotinib’s side-effect profile over Bristol’s Sprycel for Gleevec-resistant CML, Oncology CEO Epstein says.

Bristol Counters Tasigna Approval With “Improved” Sprycel Labeling In CML

Chronic-phase CML patients are recommended to take dasatinib 100 mg once daily, a dose associated with the same efficacy and less fluid retention than twice daily 70 mg dosing.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel